TGF-β oncogenic pathway in HCC: PMEPA1 as a biomarker of treatment response

Quetglas, I.M.; Sia, Daniela; Jiao, Yan; Maeda, Moe; Castro, María Magdalena Reyes; Esteller, Manel; Llovet, J.M.

doi:10.1016/s0168-8278(17)31318-1

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(34)(35)(36)(37) Recently, PMEPA1 is reported to play a key role in the transformation of TGFβ from tumor suppressor to oncogene in HCC. (38) The SLC27A5 gene, a member of the solute carrier 27A gene family, encodes a transport protein for fatty acid transport and bile acid metabolism and is exclusively expressed in the liver. (39) In patients with HCC, reduced SCL27A5 expression contributes to tumor progression and poor prognosis.…”

Section: Original Article | 211mentioning

confidence: 99%

Circulating Tumor Cell–Based Messenger RNA Scoring System for Prognostication of Hepatocellular Carcinoma: Translating Tissue‐Based Messenger RNA Profiling Into a Noninvasive Setting

et al. 2021

View full text Add to dashboard Cite

Numerous studies in hepatocellular carcinoma (HCC) have proposed tissue‐based gene signatures for individualized prognostic assessments. Here, we develop a novel circulating tumor cell (CTC)–based transcriptomic profiling assay to translate tissue‐based messenger RNA (mRNA) signatures into a liquid biopsy setting for noninvasive HCC prognostication. The HCC‐CTC mRNA scoring system combines the NanoVelcro CTC Assay for enriching HCC CTCs and the NanoString nCounter platform for quantifying the HCC‐CTC Risk Score (RS) panel in enriched HCC CTCs. The prognostic role of the HCC‐CTC RS was assessed in The Cancer Genome Atlas (TCGA) HCC cohort (n = 362) and validated in an independent clinical CTC cohort (n = 40). The HCC‐CTC RS panel was developed through our integrated data analysis framework of 8 HCC tissue‐based gene signatures and identified the top 10 prognostic genes (discoidin domain receptor tyrosine kinase 1 [DDR1], enoyl‐CoA hydratase and 3‐hydroxyacyl CoA dehydrogenase [EHHADH], androgen receptor [AR], lumican [LUM], hydroxysteroid 17‐beta dehydrogenase 6[HSD17B6], prostate transmembrane protein, androgen induced 1 [PMEPA1], tsukushi, small leucine rich proteoglycan [TSKU], N‐terminal EF‐hand calcium binding protein 2 [NECAB2], ladinin 1 [LAD1], solute carrier family 27 member 5 [SLC27A5]) highly expressed in HCC with low expressions in white blood cells. The panel accurately discriminated overall survival in TCGA HCC cohort (hazard ratio [HR], 2.0; 95% confidence interval [CI], 1.4‐2.9). The combined use of the scoring system and HCC‐CTC RS panel successfully distinguished artificial blood samples spiked with an aggressive HCC cell type, SNU‐387, from those spiked with PLC/PRF/5 cells (P = 0.02). In the CTC validation cohort (n = 40), HCC‐CTC RS remained an independent predictor of survival (HR, 5.7; 95% CI, 1.5‐21.3; P = 0.009) after controlling for Model for End‐Stage Liver Disease score, Barcelona Clinic Liver Cancer stage, and CTC enumeration count. Our study demonstrates a novel interdisciplinary approach to translate tissue‐based gene signatures into a liquid biopsy setting. This noninvasive approach will allow real‐time disease profiling and dynamic prognostication of HCC.

show abstract

Section: Original Article | 211mentioning

confidence: 99%

Circulating Tumor Cell–Based Messenger RNA Scoring System for Prognostication of Hepatocellular Carcinoma: Translating Tissue‐Based Messenger RNA Profiling Into a Noninvasive Setting

et al. 2021

View full text Add to dashboard Cite

show abstract

Chondroitin polymerizing factor (CHPF) contributes to malignant proliferation and migration of hepatocellular carcinoma cells

Lin

Tao

et al. 2020

Biochem. Cell Biol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the human digestive system, and has been recognized as a serious threat to public health worldwide. This study explored the role of chondroitin polymerizing factor (CHPF) in the development and metastasis of HCC. Immunohistochemistry analysis was performed to detect CHPF expression in HCC tissues and para-carcinoma tissues. qRT-PCR and Western blot analysis were used to determine the mRNA and protein expression of CHPF. MTT assays, colony formation assays, and flow cytometry were used to evaluate the cell proliferation, colony formation, and cell apoptosis, respectively. Wound-healing and Transwell assays were performed to evaluate cell migration. The results show that CHPF was not only up-regulated in HCC tissues compared with para-carcinoma tissues, but was also related with more advanced stages of HCC. Further studies revealed that CHPF knockdown significantly inhibited cell proliferation and colony formation, and induce cell apoptosis of HCC cells. Moreover, suppressing the expression of CHPF reduced the migration and invasiveness of HCC cells. In conclusion, we demonstrated that CHPF plays important roles in the development and progression of HCC, and high expression levels of HCC may be related with poorer prognosis. The results from this study may provide a potential therapeutic target for HCC treatment.

show abstract

TGF-β oncogenic pathway in HCC: PMEPA1 as a biomarker of treatment response

Cited by 2 publications

References 0 publications

Circulating Tumor Cell–Based Messenger RNA Scoring System for Prognostication of Hepatocellular Carcinoma: Translating Tissue‐Based Messenger RNA Profiling Into a Noninvasive Setting

Circulating Tumor Cell–Based Messenger RNA Scoring System for Prognostication of Hepatocellular Carcinoma: Translating Tissue‐Based Messenger RNA Profiling Into a Noninvasive Setting

Chondroitin polymerizing factor (CHPF) contributes to malignant proliferation and migration of hepatocellular carcinoma cells

Contact Info

Product

Resources

About